Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
Over 8.8?million Indians aged 60 and above currently live with dementia,
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
Subscribe To Our Newsletter & Stay Updated